NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Blood-based sEV Proteins for Early Detection of 2 Diabetes

Not Yet RecruitingN/A

Sponsor: Hong Kong Baptist University

Conditions: Obesity & Overweight, Prediabetes / Type 2 Diabetes

Countries: China, Hong Kong

The prevalence of diabetes in China is a significant concern. In 2019, 116.4 million adults were living with diabetes, a number expected to climb to 147.2 million by 2045. Type 2 diabetes (T2D) constitutes 95% of these cases . In Hong Kong, T2D affects an estimated 700,000 people, with prevalence keeps rising. Epidemiology data clearly show that obesity and T2D are closely associated. In our previously study, we found that integrin-β2 protein levels are significantly increased in the circulating small extracellular vesicles (sEVs) of obese/overweight individuals. Given the well-known association between integrin/ECM and the development of insulin resistance, we hypothesize that integrin-β2 and ECM1 proteins in the circulating sEVs can be used for the early detection of obese individuals at risk for T2D.This proposed study is critical to provide supporting data for the implementation of a subsequent prospective cohort study to validate whether integrin β2/ECM1 proteins in circulating sEVs can be used for the early detection of obese individuals at risk for T2D.

Eligibility overview

Sex: ALL

Age: 40 Years to 59 Years

Healthy volunteers: Yes

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Hong Kong citizens;
* Male or female;
* Aged 40-59 years;
* Able and willing to provide written informed consent;
* Willing to undergo BMI assessment and fasting blood collection after an overnight fast of at least 8 hours.

Exclusion Criteria:

* Cardiovascular disease.
* Cancer.
* History of surgery, as specified in the study protocol.
* Infectious disease.
* Osteoarthritis.
* Genetic disease.
* Pregnancy or breastfeeding.
* Suspected pregnancy.

Locations (2)

Luzhou, Sichuan, China
Kowloon Tong, Hong Kong